61Cu-based NuriPro radiodiagnostic (NUCLIDIUM)

N/A

Report date: 2025/11/20 16:02:24

NME

Base Information

Drug Name61Cu-based NuriPro radiodiagnostic (NUCLIDIUM)

Drug Alias Name61Cu-based NuriPro™ radiodiagnostic (NUCLIDIUM)61Cu-NODAGA-PSMA I&T61Cu-NuriPro

ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Copper > 61CuRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionPositron-emission tomography enhancersProstate-Specific Membrane Antigen binders

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNuclidium AG

China Registration ClassN/A

Develop Information

Active CompaniesNuclidium AG

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A